Utility of procalcitonin in a medical intensive care unit in Croatia
| Autor: | Iva Košuta, Dunja Rogić, Jaksa Babel, Mia Rora, Ana Vujaklija Brajković, Radovan Radonić, Dora Tomek, Ana Lončar Vrančić |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty medicine.drug_class Croatia Antibiotics Urine 030204 cardiovascular system & hematology Procalcitonin law.invention Sepsis 03 medical and health sciences 0302 clinical medicine Interquartile range law Internal medicine parasitic diseases Medicine Humans 030212 general & internal medicine Aged Aged 80 and over business.industry General Medicine Biomarker Pneumonia Middle Aged medicine.disease Prognosis Intensive care unit biomarker prokalcitonin sepsa pneumonija kritične bolesti Intensive Care Units ROC Curve Biomarker (medicine) Original Article business Critical illness hormones hormone substitutes and hormone antagonists |
| Zdroj: | Wiener Klinische Wochenschrift |
| ISSN: | 1613-7671 0043-5325 |
| Popis: | Summary Aims To investigate the clinical benefit of routine procalcitonin (PCT) measurement in the medical intensive care unit (ICU) of a tertiary referral hospital. Methods Adult patients with suspected infections were included. White blood cells, C‑reactive protein (CRP), and PCT were measured. Results In this study 129 patients of median age 64 years (interquartile range 39–89 years) were prospectively included. The Acute Physiology And Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores were 21 ± 14 and 7 ± 6, respectively. Intensive care unit (ICU) mortality was 22.5%. Immunocompromised patients constituted 39.5%. A significant correlation was observed between PCT and APACHE II (Spearman’s rho 0.461, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink